文章摘要
周志林,梅 勇,戴 军,杨旭辉,赵志辉.胃癌根治术后腹腔热灌注化疗对患者血清CEA、CA19-9水平及免疫功能的影响[J].,2019,19(3):477-481
胃癌根治术后腹腔热灌注化疗对患者血清CEA、CA19-9水平及免疫功能的影响
Effect of Intraperitoneal Hyperthermic Perfusion Chemotherapy on the Serum CEA, CA19-9 Levels and Immune Function of Gastric Cancer Patienst after Radical Gastrectomy
投稿时间:2018-04-30  修订日期:2018-05-24
DOI:10.13241/j.cnki.pmb.2019.03.018
中文关键词: 腹腔热灌注化疗  胃癌  CEA  CA19-9  免疫功能
英文关键词: Intraperitoneal hyperthermic perfusion chemotherapy  Gastric cancer  CEA  CA19-9  Immune function
基金项目:
作者单位E-mail
周志林 华中科技大学同济医学院附属梨园医院普通外科 湖北 武汉 430077 zhouzhilin468@163.com 
梅 勇 华中科技大学同济医学院附属梨园医院普通外科 湖北 武汉 430077  
戴 军 华中科技大学同济医学院附属梨园医院普通外科 湖北 武汉 430077  
杨旭辉 华中科技大学同济医学院附属梨园医院普通外科 湖北 武汉 430077  
赵志辉 华中科技大学同济医学院附属梨园医院普通外科 湖北 武汉 430077  
摘要点击次数: 119
全文下载次数: 111
中文摘要:
      摘要 目的:探讨胃癌根治术后腹腔灌注化疗对患者血清CEA(血清癌胚抗原,carcinoembryonic antigen)、CA19-9(糖链抗原19-9,carbohydrate antigen19-9)水平及免疫功能的影响。方法:回顾性2015年2月至2017年4月我院收治的胃癌患者临床资料,依据接受治疗方案不同分为全身静脉化疗组(对照组)和全身静脉化疗联合腹腔热灌注化疗组(观察组),每组各41例。检测和比较两组患者化疗前(治疗前)与化疗1个月后(治疗后)血清肿瘤标志物CEA、CA19-9与免疫功能指标水平的变化,治疗后毒副作用发生情况及治疗前后生活质量的改善情况。结果:治疗前,两组间血清CEA、CA19-9、CD3+、CD4+、CD8+、CD4+/CD8+水平比较差异均无统计学意义(P>0.05);观察组治疗后血清CEA、CA19-9及CD8+水平显著低于对照组,CD3+、CD4+、CD4+/CD8+水平显著高于对照组,差异有统计学意义(P<0.05);两组骨髓抑制、恶心呕吐、腹痛腹泻及肠梗发生率比较差异均不显著无统计学意义(P=0.478,0.668,0.315,0.552);观察组生活质量改善总有效率为85.37%,显著高于对照组(70.73%,P=0.017)。结论:与单纯全身化疗相比,胃癌根治术后腹腔灌注化疗可更有效降低患者血清CEA、CA19-9水平,改善患者免疫功能,提高其生活质量,且安全性较高。
英文摘要:
      ABSTRACT Objective: To investigate the effect of intraperitoneal hyperthermic perfusion chemotherapy on serum carcinoembryonic antigen (CEA), carbohydrate antigen19-9 (CA19-9) and immune function in patients with gastric cancer. Methods: The clinical data of gastric cancer patients treated in our hospital from February 2015 to April 2017 were reviewed, according to the treatment scheme they were divided into systemic venous chemotherapy group (control group) and systemic venous chemotherapy combined with intraperitoneal hyperthermic perfusion chemotherapy group (observation group), 41 cases were selected for each group. The changes of serum tumor markers CEA, CA19-9 and immune function indexes of two groups of patients before and after chemotherapy (before treatment) and after 1 months of chemotherapy (after treatment), the occurrence of toxic side effects after treatment and the improvement of quality of life before and after treatment were detected and compared. Results: There were no significant difference in the levels of serum CEA, CA19-9, CD3+, CD4+, CD8+ and CD4+/CD8+ between the two groups before the treatment (P>0.05). After treatment, the levels of serum CEA, CA19-9 and CD8+ in the observation group were significantly lower than those in the control group, and the levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were significantly higher than those in the control group, the difference was statistically significant (P<0.05). There was no significant difference in the incidence of bone marrow suppression, nausea and vomiting, abdominal pain, diarrhea and intestinal stem loss between the two groups (x2=0.502, 0.184, 1.008, 0.355, P=0.478, 0.668, 0.315, 0.552). The total effective rate of the observation group was 85.37% significantly higher than that of the control group (70.73%, P=0.017). Conclusion: Compared with simple systemic chemotherapy, intraperitoneal infusion chemotherapy after radical gastrectomy for gastric cancer can reduce serum CEA and CA19-9 levels, improve immune function and quality of life, and has high safety.
查看全文   查看/发表评论  下载PDF阅读器
关闭